U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168486) titled 'CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas' on May 13.
Brief Summary: The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells.
Based on the preclinical characteristics of the LTG2950, CAR19.20.22 tri-specific CAR T-cells the Investigators have developed the following hypotheses to be tested in our phase Ia clinical trial. The Investigators hypothesize that these novel CAR T-cells will show:
* good safety and tolerability
* a high degree of efficacy
* very good persistence...